A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis

Kidney International Reports ◽

10.1016/j.ekir.2017.03.011 ◽

2017 ◽

Vol 2 (5) ◽

pp. 800-810 ◽

Author(s):

Flavio Vincenti ◽

Fernando C. Fervenza ◽

Kirk N. Campbell ◽

Montserrat Diaz ◽

Loreto Gesualdo ◽

...

Keyword(s):

Focal Segmental Glomerulosclerosis ◽

Randomized Study ◽

Phase 2 ◽

Double Blind ◽

Steroid Resistant ◽

Double Blind Placebo ◽

Segmental Glomerulosclerosis

Download Full-text

Beta Blockade Reduces Neurocardiogenic Dysfunction: A Double Blind, Placebo Controlled Randomized Study

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(97)84200-3 ◽

1998 ◽

Vol 31 (2) ◽

pp. 114A

Author(s):

P Smits

Keyword(s):

Randomized Study ◽

Beta Blockade ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Yearbook of Paediatric Endocrinology ◽

10.1530/ey.17.14.9 ◽

2020 ◽

Author(s):

Harrison SA ◽

Bashir MR ◽

Guy CD ◽

Zhou R ◽

Moylan CA ◽

...

Keyword(s):

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Alcoholic Steatohepatitis ◽

Download Full-text

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Yearbook of Paediatric Endocrinology ◽

10.1530/ey.15.15.7 ◽

2018 ◽

Author(s):

Harrison SA ◽

Rinella ME ◽

Abdelmalek MF ◽

Trotter JF ◽

Paredes AH ◽

...

Keyword(s):

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Alcoholic Steatohepatitis ◽

Download Full-text

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

Case Medical Research ◽

10.31525/ct1-nct03926117 ◽

2019 ◽

Author(s):

Keyword(s):

Renal Disease ◽

Chronic Renal Disease ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13931968.15387072 ◽

2012 ◽

Author(s):

Michael Fisch

Keyword(s):

Ovarian Cancer ◽

Advanced Ovarian Cancer ◽

Malignant Ascites ◽

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718047281.793481249 ◽

2013 ◽

Author(s):

Jim Tsaltas

Keyword(s):

Controlled Study ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725255169.793503497 ◽

2015 ◽

Author(s):

Brendan J Canning

Keyword(s):

Receptor Antagonist ◽

Chronic Cough ◽

Phase 2 ◽

P2x3 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734506216.793579336 ◽

2020 ◽

Author(s):

Nathalie Gaspar

Keyword(s):

Adult Patients ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Metastatic Osteosarcoma ◽

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736628903.793573715 ◽

2020 ◽

Author(s):

Susanne Grässel

Keyword(s):

Knee Osteoarthritis ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Receptor Ligand ◽

Double Blind Placebo ◽

Disease Phenotypes ◽

Download Full-text

Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study

British Journal of Cancer ◽

10.1038/s41416-021-01356-3 ◽

2021 ◽

Author(s):

Ying Cheng ◽

Qiming Wang ◽

Kai Li ◽

Jianhua Shi ◽

Ying Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text